Articles published by Genentech

Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

Today 7:00 EDT

From Genentech

Via Business Wire

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

Today 2:00 EDT

From Genentech

Via Business Wire

Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

Today 1:00 EDT

From Genentech

Via Business Wire

Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

September 30, 2026

From Genentech

Via Business Wire

Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon

September 28, 2026

From Genentech

Via Business Wire

Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)

September 23, 2026

From Genentech

Via Business Wire

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

September 22, 2026

From Genentech

Via Business Wire

Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center

September 17, 2026

From Genentech

Via Business Wire

Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

September 17, 2026

From Genentech

Via Business Wire

U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments

September 10, 2026

From Genentech

Via Business Wire

Genentech Announces Manufacturing Expansion in Hillsboro, Oregon

August 20, 2026

From Genentech

Via Business Wire

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

August 18, 2026

From Genentech

Via Business Wire

FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy

July 15, 2026

From Genentech

Via Business Wire

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

July 07, 2026

From Genentech

Via Business Wire

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

July 02, 2026

From Genentech

Via Business Wire

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

June 30, 2026

From Genentech

Via Business Wire

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

June 18, 2026

From Genentech

Via Business Wire

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

June 11, 2026

From Genentech

Via Business Wire

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

June 02, 2026

From Genentech

Via Business Wire

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

June 01, 2026

From Genentech

Via Business Wire

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

May 19, 2026

From Genentech

Via Business Wire

Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

April 30, 2026

From Genentech

Via Business Wire

Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

April 24, 2026

From Genentech

Via Business Wire

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

April 21, 2026

From Genentech

Via Business Wire

Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

April 21, 2026

From Genentech

Via Business Wire

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

April 21, 2026

From Genentech

Via Business Wire

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

March 09, 2026

From Genentech

Via Business Wire

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

March 06, 2026

From Genentech

Via Business Wire

Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

March 05, 2026

From Genentech

Via Business Wire

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

March 02, 2026

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.